Business
Anteris Announces Results for the First Quarter of 2025
MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 Highlights Investigational Device Exemption (“IDE”) for the DurAVR® TH
About this update from Anteris Technologies Global Corp.
[{"type":"image","alt":"Anteris Technologies Global Corp.","displaySize":"","headline":null,"caption":"Anteris Technologies Global Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ebb91cde24fc8bfaa2bbd449d64df87a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8tNysNEA0DQBTcTu5RQZLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ebb91cde24fc8bfaa2bbd449d64df87a","width":300,"height":83}},"lazy":false},{"type":"text","content":"MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update.","length":410,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Highlights","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Investigational Device Exemption (“IDE”) for the DurAVR® THV’s global, pivotal clinical trial (the “PARADIGM Trial”), submitted to the FDA during the First Quarter","length":163,"tagName":"p"}]},{"val":[{"type":"text","content":"Scale up for commencement of the PARADIGM Trial ongoing – including expanding the Clinical Specialist Team and contracting with planned centers in the U.S., Canada and Europe","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical milestone of 100 patients successfully treated with the DurAVR® THV – comprised of de novo aortic stenosis cases including complex anatomies, and valve-in-valve patients","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported one-year clinical data for DurAVR® THV – demonstrating sustained, favourable hemodynamic outcomes, a consistent safety profile and high implant success","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Ongoing expansion of global manufacturing capacity to scale for the PARADIGM Trial and meet initial anticipated commercial demand","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Anteris included in the FTSE Russell 2000® Index","length":48,"tagName":"p"}]},{"val":[{"type...